Januari 1 - March 31

• Net sales reached SEK 3,7 million (3,5)
• Operating result amounted to -5,0 MSEK (-4,7)
• Profit after tax amounted to -5,0 MSEK (-4,8)
• Earnings per share before and after dilution amounted to -1,39 SEK (-2,49)
• Cash flow from operating activities amounted to SEK -4,1 MSEK (-6,6)

Significant events during the period

• Older men treated with CoreTherm® for benign prostate enlargement have a lower risk of a prostate cancer diagnosis later in life compared to men treated with TURP according to a new Swedish registry study.
• New study confirms the favourable effect of CoreTherm® in patients with large prostates.
• Use of Schelin Catheter® before water vapour therapy is cost-effective.

Significant events after the end of the period

• ProstaLund AB (publ) initiates strategic review due to weakened liquidity and raises loans of SEK 2.5 million.
• First treatments with CoreTherm® Eagle will be performed next week - im- portant milestone for ProstaLund.
• Per Langö leaves the board.
• ProstaLund’s CEO resigns at his own request.
• First patients treated with CoreTherm® Eagle.
• ProstaLund AB (publ) comments on trading halt and plans to decide on a directed share issue.
• ProstaLund AB (publ) has decided to carry out a directed share issue of SEK 5.5 million to several existing shareholders, subject to the subsequent approval of the Annual General Meeting.
• On May 26, ProstaLund AB appoints Malin Melander as acting CEO.
• ProstaLund AB (publ) appoints Annette Colin as interim CFO and appoints former CEO Anders Kristensson as consultant in strategic and operational matters.

Key figures

Please see attached PDF for full report.